ProQR (PRQR) AI Stock Analysis

• Market Cap: $286.18M
• Dividend Yield: N/A
• Average Volume (3M): 534.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: 7.59%
• EPS Growth: -53.46%
• Country: US
• Employees: 166
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 105,212,524
• 10 Day Avg. Volume: 796,312
• 30 Day Avg. Volume: 534,757
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.32
• Enterprise Value/Revenue: 5.58
• Enterprise Value/Gross Profit: 5.58
• Enterprise Value/Ebitda: -2.58
• 1Y Price Target: $8.33
• Price Target Upside: 195.39% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 52 Neutral
• Price Target: $3.00 ▲(6.38% Upside)

ProQR's stock score is primarily impacted by its financial performance challenges, including declining revenue and persistent losses. While technical analysis shows bullish momentum, the negative valuation metrics, such as the P/E ratio, weigh heavily on the overall score. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Innovative RNA Platform

ProQR's proprietary RNA technology platform provides a strong foundation for developing transformative therapies, offering a competitive edge in addressing genetic diseases.

Clinical Trial Authorization

The authorization for AX-0810's clinical trial marks a significant step in ProQR's pipeline, potentially leading to new treatments for cholestatic diseases, enhancing long-term growth prospects.

High Gross Profit Margin

A high gross profit margin indicates efficient cost management and strong pricing power, which can support long-term profitability as the company scales its operations.

Negative Factors

Declining Revenue

Declining revenue poses a challenge to financial stability and growth, potentially limiting the company's ability to invest in R&D and expand its market presence.

Persistent Losses

Ongoing losses and negative profit margins highlight financial struggles, which may hinder ProQR's ability to sustain operations and fund future development projects.

Negative Operating Cash Flow

Negative operating cash flow indicates cash management challenges, impacting ProQR's ability to finance its operations and invest in growth opportunities without external funding.

ProQR Business Overview & Revenue Model

Company Description

ProQR Therapeutics N.V. is a biotechnology company focused on developing transformative RNA medicines for the treatment of genetic diseases. The company operates primarily in the pharmaceutical sector, specializing in innovative therapies designed to address severe genetic disorders. ProQR’s core products include its proprietary RNA technology platform, which is utilized to create treatments aimed at correcting genetic mutations, with a focus on conditions such as cystic fibrosis and Leber congenital amaurosis.

How the Company Makes Money

ProQR generates revenue primarily through a combination of product sales, research and development collaborations, and licensing agreements. The company partners with pharmaceutical companies and research institutions to co-develop therapies, which can provide upfront payments, milestone payments, and royalties on future sales of products developed through these collaborations. Additionally, ProQR may receive funding through grants and investments aimed at advancing its clinical programs. As its drug candidates progress through clinical trials and gain regulatory approvals, the potential for revenue increases significantly, particularly if successful therapies are commercialized.

ProQR Financial Statement Overview

Summary

ProQR faces significant financial challenges, with declining revenue and persistent losses impacting profitability. The balance sheet shows moderate leverage, but negative returns on equity highlight ongoing financial struggles. Cash flow improvements are limited, with negative operating cash flow posing risks to financial stability. Overall, the company needs to address its profitability and cash flow issues to improve its financial health.

Income Statement

ProQR's income statement reveals significant challenges, with negative net profit margins and declining revenue growth. The TTM data shows a revenue decline of 13.26%, and net profit margins are deeply negative at -158.81%. Despite a high gross profit margin of 96.24%, the company struggles with profitability, as evidenced by negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet indicates moderate leverage with a debt-to-equity ratio of 0.21 in the TTM period. However, the return on equity is negative at -53.58%, reflecting ongoing losses. The equity ratio is not provided, but the company's financial stability is under pressure due to consistent negative returns.

Cash Flow

Cash flow analysis shows a slight improvement in free cash flow growth at 13.11% in the TTM period. However, operating cash flow remains negative, and the operating cash flow to net income ratio is -1.10, indicating cash flow challenges. The free cash flow to net income ratio is slightly positive at 1.02, suggesting some alignment between cash flow and net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.49M	18.91M	6.51M	4.04M	1.35M	0.00
Gross Profit	16.49M	18.91M	6.38M	1.56M	1.35M	-2.19M
EBITDA	-35.70M	-24.12M	-24.10M	-56.46M	-54.95M	-136.56M
Net Income	-39.67M	-27.76M	-28.12M	-64.89M	-61.68M	-46.61M
Balance Sheet
Total Assets	137.54M	167.96M	137.88M	171.32M	209.58M	98.73M
Cash, Cash Equivalents and Short-Term Investments	119.77M	149.41M	118.92M	94.78M	187.52M	75.84M
Total Debt	16.86M	17.22M	19.73M	21.97M	60.37M	34.28M
Total Liabilities	70.55M	79.40M	96.49M	106.21M	96.35M	42.18M
Stockholders Equity	66.98M	88.56M	41.39M	65.50M	113.83M	57.09M
Cash Flow
Free Cash Flow	-42.95M	-37.81M	20.18M	-69.22M	-26.50M	-47.98M
Operating Cash Flow	-42.20M	-36.39M	21.55M	-68.51M	-26.01M	-47.06M
Investing Cash Flow	13.60M	-4.07M	4.28M	-702.00K	-425.00K	-924.00K
Financing Cash Flow	70.18M	70.28M	-2.27M	-30.89M	136.83M	14.50M

ProQR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Positive. The current price of 2.82 is above the 20-day moving average (MA) of 2.49, above the 50-day MA of 2.31, and above the 200-day MA of 2.02, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 60.91 is Neutral, neither overbought nor oversold. The STOCH value of 70.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRQR.

ProQR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OABI	56 Neutral	$238.97M	―	-22.84%	―	6.05%	2.24%
PRQR	52 Neutral	$286.18M	-6.35	-75.99%	―	7.59%	-53.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVIR	47 Neutral	$261.09M	―	-32.38%	―	―	23.24%
HRTX	45 Neutral	$218.14M	-120.20	―	―	9.78%	98.13%
CDXS	40 Underperform	$231.08M	-3.16	-111.00%	―	-6.12%	24.99%

ProQR Corporate Events

ProQR Receives CTA Authorization for AX-0810 and Plans Investor Event

On October 20, 2025, ProQR Therapeutics announced that it received Clinical Trial Application (CTA) authorization from the Central Committee on Research Involving Human Subjects (CCMO) for a Phase 1 study of its investigational RNA editing oligonucleotide, AX-0810. This study, to be conducted in the Netherlands, will evaluate the safety, tolerability, and pharmacokinetics of AX-0810, which targets NTCP for the treatment of cholestatic diseases. The company also announced a virtual Investor and Analyst Event scheduled for November 3, 2025, to discuss the clinical development of AX-0810 and its potential impact on treating liver diseases.

ProQR Reports Q2 2025 Financial Results Amid Rising R&D Costs

On August 7, 2025, ProQR Therapeutics N.V. announced its financial results for the second quarter of 2025, ending June 30. The company reported a decrease in revenue compared to the previous year, alongside increased research and development costs, leading to a significant operating loss. This financial performance may impact ProQR’s market positioning and stakeholder confidence as the company navigates the challenges of developing treatments for rare genetic disorders.